Selected article for: "acute respiratory syndrome coronavirus and administration drug food fda"
Author: Lattanzio, Natalia; Acosta-Diaz, Cristina; Villasmil, Ricardo J; Kirkland, Zachary; Bass, Caitlin; Yenari, Sage; Conte, Jorge; Dawkins, Kevin; Fonseca, Tamela; Grimes, Cindy; Stewart, Angie; Geary, Mary E; Vore, Harold; Hamad, Karen; Wiese-Rometsch, Wilhelmine; Fiorica, James; Gordillo, Manuel; Mercado, Roberto; Voelker, Kirk
Title: Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
  • Cord-id: fpk63k4j
  • Document date: 2021_7_30
    • ID: fpk63k4j
    Snippet: On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic windo
    Document: On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.

    Search related documents:
    Co phrase search for related documents
    • access program expand and longitudinal study: 1
    • activity relationship and longitudinal study: 1, 2, 3
    • longitudinal study and low hospital: 1, 2, 3, 4, 5, 6